R D Press

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy
    Jennifer Laudadio
    Department of Pathology, Oregon Health and Science University, Portland, OR, USA
    J Mol Diagn 10:177-80. 2008
  2. ncbi A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response
    Richard D Press
    Department of Pathology, Center for Hematologic Malignancies, Cancer Institute, and Howard Hughes Medical Institute, Oregon Health and Science University, Portland, Oregon 97201, USA
    Clin Cancer Res 13:6136-43. 2007
  3. ncbi Hereditary hemochromatosis: impact of molecular and iron-based testing on the diagnosis, treatment, and prevention of a common, chronic disease
    R D Press
    Department of Pathology, Oregon Health Sciences University, Portland 97201, USA
    Arch Pathol Lab Med 123:1053-9. 1999
  4. ncbi Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders
    Richard D Press
    Department of Pathology and Medical Genetics, Oregon Health and Science University, Portland 97201, USA
    Arch Pathol Lab Med 126:1304-18. 2002
  5. ncbi Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib
    Richard D Press
    Department of Pathology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201, USA
    Blood 114:2598-605. 2009
  6. ncbi BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML
    Richard D Press
    Department of Pathology, Oregon Health and Science University, Portland, OR 97201, USA
    Blood 107:4250-6. 2006
  7. ncbi Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
    D W Sherbenou
    Cell and Developmental Biology, Oregon Health and Science University, Portland, OR 97239, USA
    Leukemia 21:489-93. 2007
  8. ncbi Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia
    D W Sherbenou
    Cell and Developmental Biology, Oregon Health and Science University, Portland, OR, USA
    Leukemia 22:1184-90. 2008
  9. ncbi Real-time polymerase chain reaction with fluorescent hybridization probes for the detection of prevalent mutations causing common thrombophilic and iron overload phenotypes
    S B Parks
    Departments of Molecular and Medical Genetics, Oregon Health Sciences University, Portland, USA
    Am J Clin Pathol 115:439-47. 2001
  10. ncbi Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease
    T G Deloughery
    Department of Medicine, Oregon Health Sciences University, Portland 97201 3098, USA
    Circulation 94:3074-8. 1996

Research Grants

  1. Bcr-Abl RNA levels to monitor STI571 leukemia therapy
    Richard Press; Fiscal Year: 2004

Collaborators

Detail Information

Publications17

  1. ncbi An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy
    Jennifer Laudadio
    Department of Pathology, Oregon Health and Science University, Portland, OR, USA
    J Mol Diagn 10:177-80. 2008
    ..These findings demonstrate that kinase domain insertions are an alternative (and not entirely uncommon) mutational mechanism in CML patients undergoing kinase inhibitor therapy...
  2. ncbi A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response
    Richard D Press
    Department of Pathology, Center for Hematologic Malignancies, Cancer Institute, and Howard Hughes Medical Institute, Oregon Health and Science University, Portland, Oregon 97201, USA
    Clin Cancer Res 13:6136-43. 2007
    ..Although CCR is usually durable, a minority of patients relapse. Biomarkers capable of predicting those CCR patients with a higher risk of relapse would improve therapeutic management...
  3. ncbi Hereditary hemochromatosis: impact of molecular and iron-based testing on the diagnosis, treatment, and prevention of a common, chronic disease
    R D Press
    Department of Pathology, Oregon Health Sciences University, Portland 97201, USA
    Arch Pathol Lab Med 123:1053-9. 1999
    ..To review the current state-of-the-art regarding the role of iron- and DNA-based testing on the detection, treatment, and prevention of hereditary hemochromatosis (HH), the most common single-gene disorder in white people...
  4. ncbi Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders
    Richard D Press
    Department of Pathology and Medical Genetics, Oregon Health and Science University, Portland 97201, USA
    Arch Pathol Lab Med 126:1304-18. 2002
    ..As FVL is currently the most common recognized familial thrombophilia, it is hoped that these recommendations will assist laboratorians and clinicians caring for patients (and families) with this common mutation...
  5. ncbi Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib
    Richard D Press
    Department of Pathology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201, USA
    Blood 114:2598-605. 2009
    ..We conclude that the currently recommended 10-fold threshold to trigger mutation screening is insensitive and not universally applicable...
  6. ncbi BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML
    Richard D Press
    Department of Pathology, Oregon Health and Science University, Portland, OR 97201, USA
    Blood 107:4250-6. 2006
    ..1; 95% CI, 3.1-22; P < .001). The achievement of either a 2-log molecular response at the time of CCR or a 3-log response anytime thereafter is a significant and independent prognostic marker of subsequent progression-free survival...
  7. ncbi Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
    D W Sherbenou
    Cell and Developmental Biology, Oregon Health and Science University, Portland, OR 97239, USA
    Leukemia 21:489-93. 2007
    ..BCR-ABL-kinase domain mutations in patients with a stable CCR are infrequent, and their detection does not consistently predict relapse. Alternative mechanisms must be responsible for disease persistence in the majority of patients...
  8. ncbi Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia
    D W Sherbenou
    Cell and Developmental Biology, Oregon Health and Science University, Portland, OR, USA
    Leukemia 22:1184-90. 2008
    ..Thus, it will be important to investigate the prognostic impact of coexpression of deletion mutants in CML patients during imatinib treatment...
  9. ncbi Real-time polymerase chain reaction with fluorescent hybridization probes for the detection of prevalent mutations causing common thrombophilic and iron overload phenotypes
    S B Parks
    Departments of Molecular and Medical Genetics, Oregon Health Sciences University, Portland, USA
    Am J Clin Pathol 115:439-47. 2001
    ..In addition to these practical advantages, the FRET method is diagnostically accurate and clinically predictive of phenotypic, disease-associated manifestations...
  10. ncbi Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease
    T G Deloughery
    Department of Medicine, Oregon Health Sciences University, Portland 97201 3098, USA
    Circulation 94:3074-8. 1996
    ..We determined the prevalence of this mutation in many subjects with and without vascular disease and related it to homocysteine and folate levels...
  11. ncbi Identification of cytomegalovirus in a liquid-based gynecologic sample using morphology, immunohistochemistry, and DNA real-time PCR detection
    Harmanjatinder S Sekhon
    Division of Cytopathology and Division of Molecular Diagnostics, Department of Pathology, Oregon Health and Sciences University, Portland, Oregon 97201, USA
    Diagn Cytopathol 30:411-7. 2004
    ..These observations suggest that a liquid-based preparation can be used to assess CMV infection morphologically, immunohistochemically, and by real-time PCR...
  12. ncbi BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
    Daniel W Sherbenou
    Cell and Developmental Biology, Oregon Health and Science University, Portland, OR, USA
    Blood 116:3278-85. 2010
    ..Regulatory domain mutations are uncommon but may explain resistance in some patients without mutations in the kinase domain...
  13. ncbi Quantitative real-time PCR with automated sample preparation for diagnosis and monitoring of cytomegalovirus infection in bone marrow transplant patients
    Kyeong Man Hong
    Department of Pathology, Oregon Health and Science University, Portland, OR 97201, USA
    Clin Chem 50:846-56. 2004
    ....
  14. ncbi ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts
    Neil B Quigley
    J Mol Diagn 10:475-6; author reply 476. 2008
  15. ncbi HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening
    James C Barton
    Southern Iron Disorders Center, Birmingham, Alabama, USA
    Genet Test 11:269-75. 2007
    ..Screening using an elevated TfSat criterion would fail to detect some C282Y homozygotes aged 25-29 years...
  16. ncbi Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
    Susan Branford
    Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 112:3330-8. 2008
    ..This indicates that the IS can deliver accurate comparison of molecular response rates between clinical trials when measured by different laboratories...
  17. ncbi An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR
    Martin C Muller
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Haematologica 92:970-3. 2007
    ..5 mL samples tested positive. For higher dilutions, a PB volume of 5 or 10 ml was required to improve sensitivity. The study showed the feasibility of RQ-PCR standardization independent of the PCR machine used...

Research Grants1

  1. Bcr-Abl RNA levels to monitor STI571 leukemia therapy
    Richard Press; Fiscal Year: 2004
    ..abstract_text> ..